Y
Yanhui Yin
Researcher at Sinovac Biotech
Publications - 3
Citations - 1233
Yanhui Yin is an academic researcher from Sinovac Biotech. The author has contributed to research in topics: Inactivated vaccine & Virus. The author has an hindex of 2, co-authored 3 publications receiving 846 citations.
Papers
More filters
Journal ArticleDOI
Development of an inactivated vaccine candidate for SARS-CoV-2.
Qiang Gao,Linlin Bao,Haiyan Mao,Lin Wang,Kangwei Xu,Minnan Yang,Li Yajing,Ling Zhu,Nan Wang,Zhe Lv,Hong Gao,Ge Xiaoqin,Biao Kan,Yaling Hu,Jiangning Liu,Fang Cai,Deyu Jiang,Yanhui Yin,Cheng-Feng Qin,Jing Li,Xuejie Gong,Xiuyu Lou,Wen Shi,Dongdong Wu,Hengming Zhang,Zhu Lang,Wei Deng,Li Yurong,Jinxing Lu,Changgui Li,Xiangxi Wang,Weidong Yin,Yanjun Zhang,Chuan Qin +33 more
TL;DR: Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
Posted ContentDOI
Rapid development of an inactivated vaccine for SARS-CoV-2
Qiang Gao,Linlin Bao,Haiyan Mao,Lin Wang,Kangwei Xu,Minnan Yang,Li Yajing,Ling Zhu,Nan Wang,Zhe Lv,Hong Gao,Ge Xiaoqin,Biao Kan,Yaling Hu,Jiangning Liu,Fang Cai,Deyu Jiang,Yanhui Yin,Cheng-Feng Qin,Jing Li,Xuejie Gong,Xiuyu Lou,Wen Shi,Dongdong Wu,Hengming Zhang,Zhu Lang,Wei Deng,Li Yurong,Jinxing Lu,Changgui Li,Xiangxi Wang,Weidong Yin,Yanjun Zhang,Chuan Qin +33 more
TL;DR: Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe, and data support the rapid clinical development of SARS-CoV-2 vaccines for humans.
Patent
Human enterovirus 71-type C4-subtype lethal strain SD095 and its application
TL;DR: Wang et al. as discussed by the authors provided a human enterovirus71-type C4-subtype lethal strain SD095 with the accession number of CGMCC NO.6601 and its application.